Autonomix Medical, Inc. announced that effective immediately, Brad Hauser has been appointed as President. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman of the Board and will continue to guide the Company forward on corporate and capital markets strategies. Hauser is a globally renowned medical technology innovation leader and seasoned executive with more than 20 years of experience building teams that bring unique energy-based technologies from concept, through design validation, clinical studies, regulatory approvals, manufacturing, and commercialization.

Over the course of his career, he has been a visionary for top laser, radiofrequency, sound and cold technologies treating a broad range of indications from vascular to adipose tissue to skin. Previously, he was part of the teams that successfully took three companies through acquisition, Soliton, Inc., ZELTIQ Aesthetics, and Reliant Technologies, and has been an officer of four public companies. Mr. Hauser joins Autonomix having most recently served as the Chief Operating Officer at Beauty Health, a global category-creating company delivering million of skin health experiences every year.

While at Beauty Health, he led operations, marketing, technology, research and development, quality assurance and regulatory affairs and oversaw product development with a focus on continuing to advance the HydraFacial delivery systems and pioneer innovation. Prior to his appointment at Beauty Health, Mr. Hauser served as President and Chief Executive Officer at Soliton, where he led the RESONIC brand from early commercial launch through acquisition by Allergan Aesthetics, an AbbVie company, for $550 million enterprise value in 2021. Following the acquisition, he served as President and Chief Executive Officer at Soliton within Allergan Aesthetics, an AbbVie company until July 2022.

Prior to that, he served in multiple roles at ZELTIQ Aesthetics, Inc. including Vice President of Product and Clinical Strategy, Vice President of Research and Development and Senior Vice President of Research and Development, where he helped build the CoolSculpting franchise from a $100 million to $350 million+ global business over 4 years and a sale to Allergan for $2.4 billion in 2017. Following the acquisition, his role increased further to serve as Vice President, R&D and General Manager for the Coolsculpting and Body Contouring portfolio at Allergan Pharmaceuticals. Prior to ZELTIQ, Mr. Hauser held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis and Managing Director of Product and Clinical Marketing at Solta Medical.

He currently sits on the Board of Directors of Candesant Biomedical and the American Society of Laser Medicine and Surgery, Inc. (ASLMS). Mr. Hauser holds a Bachelor of Arts in Human Biology from Stanford University.